Back to Newsroom
Back to Newsroom

CNS Pharmaceuticals to Participate at the Virtual Investor Ask the CEO Conference

Thursday, 19 October 2023 09:05 AM

CNS Pharmaceuticals, Inc.

Live moderated webcast with John Climaco, Chief Executive Officer of CNS Pharmaceuticals on Tuesday, October 24th at 4:00 PM ET

HOUSTON, TX / ACCESSWIRE / October 19, 2023 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will participate at the Virtual Investor Ask the CEO Conference on Tuesday, October 24, 2023 at 4:00 PM ET.

The "Ask the CEO" conference is intended to provide the investment community with access to ask their questions directly to management. Investors and interested parties will have the opportunity to submit questions live during the event. Questions can also be pre-submitted leading up to the event through Participating companies will answer as many questions as possible during the event.

A live video webcast of the presentation will be available on the Events page of the Investors section of the Company's website ( A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.

About CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.

For more information, please visit, and connect with the Company on Twitter, Facebook, and LinkedIn.


Investor Relations Contact
Jenene Thomas
[email protected]

SOURCE: CNS Pharmaceuticals, Inc.

Back to newsroom
Back to Newsroom
Share by: